A Study to Evaluate SSGJ-707 in Advanced Gynecologic Cancer Patients

Recruiting now · Phase 2

Conditions studied: Advanced/recurrent Endometrial Cancer and Platinum-resistant Ovarian Cancer

In brief

This is an open, multicenter Phase II clinical study of SSGJ-707 combined with chemotherapy in the treatment of advanced/recurrent endometrial cancer and platinum-resistant ovarian cancer. The objective is to evaluate the safety, tolerability and antitumor activity of SSGJ-707 in the treatment of advanced/recurrent endometrial cancer and platinum-resistant ovarian cancer.

Key facts

Study ID

NCT06522828

Run by

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

People needed

80

Starts

2024-10-10

Expected to finish

2026-08-01

Last updated by the study team

2024-10-21

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age:18-75 years old
• Advanced endometrial cancer and platinum-resistant ovarian cancer
• Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
• Expected survival >=12 weeks.
• Signed informed consent form.

You may not qualify if…

• Known uncontrolled or symptomatic central nervous system metastatic disease.
• Adverse events (with exception of alopecia and fatigue) from any prior anticancer therapy of grade >1 (National Cancer Institute Common terminology Criteria [NCI CTCAE] v.5.0).
• Inadequate organ or bone marrow function.
• Pregnant or breast-feeding woman.
• Known allergies, hypersensitivity, or intolerance to SSGJ-707 The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Where it is running

• Chongqing Cancer Hospital — Chongqing, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.